



Agile Therapeutics to Host First Quarter 2020 Financial Results and Business Update Conference Call on Tuesday, May 5, 2020

April 23, 2020

Live Conference Call and Webcast at 4:30 p.m. ET

PRINCETON, N.J., April 23, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women's healthcare company, today announced it will report first quarter 2020 financial results after the market close on Tuesday, May 5, 2020. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss the Company's financial results and provide a business update.

Investors interested in listening to the conference call may do so by dialing (877) 407-2991 for domestic callers or (201) 389-0925 for international callers. A live webcast will be available in the Events and Presentations section of the Investor Relations page at <https://ir.agiletherapeutics.com/events-and-presentations/>, or by [clicking here](#).

Please log in approximately 10 minutes prior to the scheduled start time. The archived webcast will be available in the Events and Presentations section of the company's website.

About Agile Therapeutics, Inc.

Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today's women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company's website.

Follow Agile on LinkedIn and Twitter: @AgileTher.

Source: Agile Therapeutics

Contact: Investor Relations -- 609-683-1880



Source: Agile Therapeutics, Inc.